Take (BOM:532890) Marketable Securities: ₹0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532890 Take Ltd BOM:532890
38 GF Score
Price ₹13.94
! 3 Warning Signs
View Full Analysis

What is Take Marketable Securities?

Take BOM:532890 +4.97% 38 Marketable Securities is ₹0.0 Mil as of Jun. 2026. GuruFocus rates BOM:532890 with a GF Score™ of 38/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Take's Marketable Securities for the quarter that ended in Jun. 2026 was ₹0.0 Mil.

Take's annual Marketable Securities declined from Mar. 2024 (₹5.8 Mil) to Mar. 2025 (₹0.0 Mil) but then increased from Mar. 2025 (₹0.0 Mil) to Mar. 2026 (₹183.8 Mil).

Take  (BOM:532890) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Take Marketable Securities Related Terms

Take Marketable Securities Historical Data

* Premium members only.

The historical data trend for Take's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Take Marketable Securities Chart

Take Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 60.36 6.13 5.80 0.04 183.81

Take Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 144.41 0.00 183.81 0.00
BOM:532890
38GF Score
Take Ltd BOM:532890
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Take Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹0.0 Mil mean?
Take (BOM:532890) has a Marketable Securities of ₹0.0 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Take and its competitors.
Is Take's Marketable Securities too high?
Take's current Marketable Securities is ₹0.0 Mil. Overall, Take has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Take's Marketable Securities compare to VEEV and BTSG?
Take's Marketable Securities of ₹0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Healthcare Providers & Services company?
A good Marketable Securities depends on the Healthcare Providers & Services industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Take and its competitors. Take's current Marketable Securities is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Take stock overvalued right now?
Take (BOM:532890) has a current Marketable Securities of ₹0.0 Mil. The current Marketable Securities is ₹0.0 Mil. Take's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Take (BOM:532890), the current Marketable Securities is ₹0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Take Business Description

Other Exchanges TAKE:India
Address No.56, Old No. 116, Dr. Radhakrishnan Salai, 4th Floor, Ragas Building, Mylapore, Chennai, TN, IND, 600004
Take Solutions Ltd is a technology solutions provider specializing in Life Sciences and Supply Chain Management services. The company offers integrated services including clinical research, generics support, regulatory affairs, pharmacovigilance, and data sciences. It supports pharmaceutical, biotech, and medical device companies to various countries with technology-backed solutions that enhance drug development and regulatory compliance. Revenue is driven by its broad portfolio of IT-enabled services focused on the life sciences industry and supply chain management, catering to a client base of innovators, generics manufacturers, and biotech firms.
38GF Score

Get the complete analysis for BOM:532890

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹13.94
Price